Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHASEBIO PHARMACEUTICALS, INC.

(PHAS)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
2.85(c) 2.8(c) 2.93(c) 2.92(c) 2.89(c) Last
275 389 984 572 358 315 355 404 425 116 Volume
-4.36% -1.75% +4.64% -0.34% -1.03% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 10,8 M - -
Net income 2021 -117 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,13x
Yield 2021 -
Sales 2022 12,5 M - -
Net income 2022 -107 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,47x
Yield 2022 -
Capitalization 139 M 139 M -
Capi. / Sales 2021 12,9x
Capi. / Sales 2022 11,1x
Nbr of Employees 55
Free-Float 93,0%
More Financials
Company
Phasebio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The CompanyÔÇÖs lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which the Company is developing for the treatment of patients on... 
More about the company
Ratings of PhaseBio Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about PHASEBIO PHARMACEUTICALS, INC.
09/15PHASEBIO PHARMACEUTICALS : Appoints William D. Humphries to Board of Directors (..
PU
09/15PHASEBIO PHARMACEUTICALS INC : Change in Directors or Principal Officers, Regula..
AQ
09/15PhaseBio Pharmaceuticals, Inc. Announces Board Changes
CI
09/15PHASEBIO PHARMACEUTICALS : Appoints William D. Humphries to Board of Directors
BU
08/31PHASEBIO PHARMACEUTICALS : to Present at 23rd Annual H.C. Wainwright Global Inve..
BU
08/12PHASEBIO PHARMACEUTICALS : Achieved interim enrollment milestone with first 143 ..
PU
08/12PHASEBIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
AQ
08/12PHASEBIO PHARMACEUTICALS INC : Results of Operations and Financial Condition, Re..
AQ
08/12PhaseBio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarte..
CI
08/12PHASEBIO PHARMACEUTICALS : Q2 Loss Narrows
MT
08/12PHASEBIO PHARMACEUTICALS : Earnings Flash (PHAS) PHASEBIO PHARMACEUTICALS Report..
MT
08/12PHASEBIO PHARMACEUTICALS : Earnings Flash (PHAS) PHASEBIO PHARMACEUTICALS Report..
MT
08/12PHASEBIO PHARMACEUTICALS : Reports Second-Quarter 2021 Financial Results and Rec..
BU
08/12PHASEBIO PHARMACEUTICALS : Achieves Enrollment Milestones Supporting Interim Ana..
BU
08/12PhaseBio Pharmaceuticals, Inc. Achieves Enrollment Milestones Supporting Inte..
CI
More news
News in other languages on PHASEBIO PHARMACEUTICALS, INC.
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2019WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on PHASEBIO PHARMACEUTICALS, INC.
More recommendations
Chart PHASEBIO PHARMACEUTICALS, INC.
Duration : Period :
PhaseBio Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHASEBIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 2,89 $
Average target price 14,33 $
Spread / Average Target 396%
EPS Revisions
Managers and Directors
Jonathan P. Mow Chief Executive Officer & Director
John P. Sharp Chief Financial Officer
Clay Bernardin Thorp Executive Chairman
John S. Lee Chief Medical Officer
Nancy J. Hutson Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PHASEBIO PHARMACEUTICALS, INC.-13.99%139
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
WUXI APPTEC CO., LTD.35.75%69 350
REGENERON PHARMACEUTICALS34.93%67 775
VERTEX PHARMACEUTICALS-20.33%48 850